Search results for "Loop diuretic"

showing 8 items of 8 documents

Loop diuretics decrease the renal elimination rate and increase the plasma levels of trimethylamine‐N‐oxide

2018

Aims Trimethylamine-N-oxide (TMAO) is a novel cardiovascular risk marker. We explored the association of commonly used cardiovascular medications with TMAO levels in patients and validated the identified associations in mice. Methods Detailed history of drug treatment was recorded in 300 patients with cardiovascular disease without diabetes in an observational, cross-sectional study. Animal study was performed in CD1 mice. Results Median plasma TMAO (interquartile range) level was 2.144 (1.570-3.104) μmol l-1 . Among nine cardiovascular drug groups, the use of loop diuretics (0.510 ± 0.296 in users vs. 0.336 ± 0.272 in nonusers, P = 0.008) and mineralocorticoid receptor antagonists (0.482 ±…

0301 basic medicineMalemedicine.medical_specialtyOrganic anion transporter 1medicine.drug_classTrimethylamine N-oxide030204 cardiovascular system & hematologyKidneyExcretion03 medical and health scienceschemistry.chemical_compoundMethylaminesMice0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsInternal medicineBlood plasmamedicineAnimalsHumansPharmacology (medical)AgedPharmacologybiologyChemistryArea under the curveFurosemideCardiovascular AgentsHeartOriginal ArticlesLoop diureticMiddle AgedProbenecid030104 developmental biologyEndocrinologyCross-Sectional StudiesLiverCardiovascular Diseasesbiology.proteinFemaleBiomarkersmedicine.drug
researchProduct

Old and New Drugs for Treatment of Advanced Heart Failure.

2020

Background: Advanced heart failure (HF) is a progressive disease with high mortality and limited medical therapeutic options. Long-term mechanical circulatory support and heart transplantation remain goldstandard treatments for these patients; however, access to these therapies is limited by the advanced age and multiple comorbidities of affected patients, as well as by the limited number of organs available. Methods: Traditional and new drugs available for the treatment of advanced HF have been researched. Results: To date, the cornerstone for the treatment of patients with advanced HF remains water restriction, intravenous loop diuretic therapy and inotropic support. However, many patien…

Inotropemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatment030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFurosemideDrug DiscoverymedicineHumansDecompensation030212 general & internal medicine: Dobutamine dopamine nitroglycerine sodium nitroprusside vaptans ivabradineIntensive care medicineDiureticsSimendanPharmacologyHeart transplantationHeart Failurebusiness.industryLevosimendanLoop diureticmedicine.diseasePrognosisOmecamtiv mecarbilIstaroximeHeart failurebusinessmedicine.drugCurrent pharmaceutical design
researchProduct

Optimal decongestive therapy in acute decompensated heart failure syndromes: Far from being solved

2014

We have read with great interest the article entitled “Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial” [1]. First, we would like to commend the authors for their effort in carrying out this investigator-initiated clinical trial by testing the prognostic effect of three decongestive strategies in the management of patients with acute decompensated heart failure (ADHF). The analysis of the data revealed no-significant differences in the in-hospital and post-discharge outcomes between high (HDF) vs low-dose furosemide infusion (LDFD); the addition of low-dose dopamine infusion…

Malemedicine.medical_specialtyCardiotonic AgentsAcute decompensated heart failuremedicine.drug_classDopamineFurosemideDopamineInternal medicinemedicineHumansDiureticsBeneficial effectsHeart Failurebusiness.industryOptimal treatmentLow doseFurosemideLoop diureticmedicine.diseaseClinical trialCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugInternational Journal of Cardiology
researchProduct

Continuous ambulatory peritoneal dialysis and clinical outcomes in patients with refractory congestive heart failure.

2012

A B S T R A C T Introduction and objectives: Peritoneal dialysis has been proposed as a therapeutic alternative for patients with refractory congestive heart failure. The objective of this study was to assess its effect on long-term clinical outcomes in patients with advanced heart failure and renal dysfunction. Methods: A total of 62 patients with advanced heart failure (class III/IV), renal dysfunction (glomerular filtration<60 mL/min/1.73 m 2 ), persistent fluid congestion despite loop diuretic treatment and at least 2 previous hospitalizations for heart failure were invited to participate in a continuous ambulatory peritoneal dialysis program. Of these, 34 patients were excluded and adj…

Malemedicine.medical_specialtymedicine.drug_classEndpoint Determinationmedicine.medical_treatmentDrug ResistanceUltrafiltrationPeritoneal dialysisCohort StudiesPeritoneal Dialysis Continuous AmbulatoryRisk FactorsInternal medicineClinical endpointmedicineRisk of mortalityHumansProspective StudiesPropensity ScoreAgedHeart Failurebusiness.industryContinuous ambulatory peritoneal dialysisHazard ratioGeneral MedicineLoop diureticmedicine.diseaseSurvival AnalysisConfidence intervalSurgeryTreatment OutcomeHeart failureCardiologyFemalebusinessFollow-Up StudiesRevista espanola de cardiologia (English ed.)
researchProduct

Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization …

2012

Recent observations in chronic stable heart failure suggest that high-dose loop diuretics (HDLDs) have detrimental prognostic effects in patients with high blood urea nitrogen (BUN), but recent findings have also indicated that diure- tics may improve renal function. Carbohydrate antigen 125 (CA125) has been shown to be a surrogate of systemic congestion. We sought to explore whether BUN and CA125 modulate the mortality risk associated with HDLDs following a hospitalization for acute heart failure (AHF). Methods and results We analysed 1389 consecutive patients discharged for AHF. CA125 and BUN were measured at a mean of 72+12 h after admission. HDLDs (≥120 mg/day in furosemide equivalent d…

Malemedicine.medical_specialtymedicine.drug_classRenal functionGastroenterologyRisk AssessmentLoop diureticsBlood Urea NitrogenCohort StudiesSodium Potassium Chloride Symporter InhibitorsFurosemideInternal medicinemedicineHumansProspective StudiesMortalityProspective cohort studyBlood urea nitrogenAgedAged 80 and overHeart Failurebusiness.industryHazard ratioFurosemideAcute heart failureLoop diureticMiddle Agedmedicine.diseaseConfidence intervalfemale genital diseases and pregnancy complicationsHospitalizationBlood urea nitrogenEndocrinologyCarbohydrate antigen 125Heart failureCA-125 AntigenAcute DiseaseFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugFollow-Up StudiesEuropean journal of heart failure
researchProduct

Antigen carbohydrate 125 and creatinine on admission for prediction of renal function response following loop diuretic administration in acute heart …

2014

The use of loop diuretics in acute heart failure (AHF) is largely empirical and has been associated with renal function impairment by reducing renal perfusion but also renal improvement by decreasing renal venous congestion. Antigen carbohydrate 125 (CA125) has emerged as a proxy for fluid overload. We sought to evaluate whether the early changes in creatinine (ΔCr) induced by intravenous furosemide doses (ivFD) differ among clinical groups defined by overload status (CA125) and creatinine on admission (Cr).We included 526 consecutive patients admitted for AHF. All patients received intravenous furosemide for the first 48 hours. CA125 and Cr were dichotomized at 35 U/ml and 1.4 mg/dl, respe…

Malemedicine.medical_specialtymedicine.drug_classUrologyRenal functionKidneyCohort Studieschemistry.chemical_compoundPatient AdmissionAntigenSodium Potassium Chloride Symporter InhibitorsPredictive Value of TestsInternal medicinemedicineHumansIn patientInfusions IntravenousAgedAged 80 and overHeart FailureCreatininebusiness.industryFurosemideCarbohydrateLoop diureticMiddle Agedmedicine.diseaseEndocrinologychemistryHeart failureCA-125 AntigenCreatinineAcute DiseaseFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugFollow-Up StudiesInternational journal of cardiology
researchProduct

Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure.

2012

Aims Continuous ambulatory peritoneal dialysis (CAPD) has been proposed as an additional therapeutic resource for patients with advanced congestive heart failure (CHF). The objective of this study was to determine the therapeutic role of CAPD, in terms of surrogate endpoints, in the management of patients with advanced CHF and renal dysfunction. A total of 57 candidates with New York Heart Association (NYHA) class III/IV CHF, renal dysfunction (glomerular filtration rate , 60 mL/min/1.73 m 2 ), persistent fluid congestion despite loop diuretic treatment, and at least two previous hospitalizations for acute heart failure (AHF) were invited to be included in the CAPD programme; however, 25 pa…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentRenal functionurologic and male genital diseasesKidneySeverity of Illness IndexPeritoneal dialysisPeritoneal Dialysis Continuous AmbulatoryInternal medicineSurveys and QuestionnairesmedicineAmbulatory CareHumanscardiovascular diseasesProspective StudiesRenal InsufficiencyProspective cohort studyHeart Failurebusiness.industrySurrogate endpointContinuous ambulatory peritoneal dialysisLoop diureticBrain natriuretic peptidemedicine.diseaseHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersGlomerular Filtration RateEuropean journal of heart failure
researchProduct

Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study

2021

AIMS: Although acute heart failure (AHF) with volume overload is treated with loop diuretics, their dosing and type of administration are mainly based upon expert opinion. A recent position paper from the Heart Failure Association (HFA) proposed a step-wise pharmacologic diuretic strategy to increase the diuretic response and to achieve rapid decongestion. However, no study has evaluated this protocol prospectively. METHODS AND RESULTS: The Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure (ENACT-HF) study is an international, multicentre, non-randomized, open-label, pragmatic study in AHF patients on chronic loop diuretic therapy, admitted to the hospital for intravenous …

medicine.drug_classmedicine.medical_treatmentStudy DesignsDecongestionVolume overloadDiuresisNatriuresisSodium Potassium Chloride Symporter InhibitorsFurosemideAcute heart failure; Diuretics; Urinary sodium; Decongestion; ProtocolmedicineClinical endpointProtocolHumansDiseases of the circulatory (Cardiovascular) systemInfusions IntravenousDiureticsHeart FailureUrinary sodiumStudy Designbusiness.industryFurosemideAcute heart failureLoop diureticmedicine.diseaseAnesthesiaHeart failureRC666-701DiureticCardiology and Cardiovascular Medicinebusinessmedicine.drugESC Heart Failure
researchProduct